Freeline Therapeutics FRLN is set to give its latest quarterly earnings report on Tuesday, 2023-04-04. Here's what investors need to know before the announcement.
Analysts estimate that Freeline Therapeutics will report an earnings per share (EPS) of $-0.28.
Freeline Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Past Earnings Performance
Last quarter the company beat EPS by $0.24, which was followed by a 1.22% drop in the share price the next day.
Here's a look at Freeline Therapeutics's past performance and the resulting price change:
| Quarter | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.44 | -0.51 | -0.68 | -0.68 |
| EPS Actual | -0.20 | -0.95 | -0.63 | -0.97 |
| Price Change % | -1.22% | 6.83% | -2.17% | -0.89% |
Stock Performance
Shares of Freeline Therapeutics were trading at $0.455 as of March 31. Over the last 52-week period, shares are down 54.77%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
To track all earnings releases for Freeline Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
